Education
About Us
Working with TipRanks
Follow Us
Tenaya Therapeutics (TNYA)
NASDAQ:TNYA
TNYA Analyst Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
TNYA Stock 12 Month Forecast
Average Price Target
$10.14
▲(704.76% Upside)
| Highest Price Target$40.00 | Average Price Target$10.14 | Lowest Price Target$3.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$5
Buy
296.83%
Upside
Reiterated
09/02/25
Canaccord Genuity
$6
Buy
376.19%
Upside
Reiterated
08/29/25
Promising Developments and Strategic Approaches in Tenaya Therapeutics' Gene Therapy Programs Drive Buy RatingTNYA has 2 data updates coming in 4Q25: one from TN-201 for the treatment of MYBPC3-associated HCM (longer cohort 1 follow up and initial cohort 2 data) and another from its 2nd program TN-401 for PKP2-ARVC (initial cohort 1 data). Ahead of these updates the co hosted a webcast (slides here, replay here) to dive into the nuance of protein expression and measurement in both diseases. As a reminder, there is not a clear "threshold" or target protein level in either disease. Instead, the goal is to increase protein levels from baseline, and even modest changes may provide clinically meaningful benefit. As such, ability to accurately measure small changes in protein level is critical, and the webcast focused on TNYA's collaboration with Dr. Michael Previs (U of Vermont) to develop its mass spec based quantification assays for both programs.
LifeSci Capital
$3
Buy
138.10%
Upside
Reiterated
08/29/25
Promising Advancements and Strategic Approaches Underpin Buy Rating for Tenaya TherapeuticsTenaya Therapeucs (Nasdaq: TNYA) hosted a KOL event with Dr. Michael Previs, a leading cardiac protein quanfic aon expert, who shared his experse, experience, and insights into quanfic aon methods being used in Tenaya’s ongoing clinical studies for MYBPC3- HCM (with TN-201) and PKP2-ARVC (with TN-401). Importantly, Tenaya and Dr. Previs shared insights into their approach to normalizing cardiac protein expression, which focuses on normalizing to a consistently expressed cardiomyocyte-specific proteins like myosin heavy chain (MYH-6/7) vs more tradional references like GAPDH. Here, Dr. Previs generated historical data using liquid chromatography–mass spectrometry (LCMS or mass-spec) to analyze cardiac ssue from MYBPC3-HCM paen ts and donor controls.
William Blair
―
Buy
―
Reiterated
08/26/25
Morgan Stanley
$5
Buy
296.83%
Upside
Reiterated
08/26/25
TD Cowen
―
Buy
―
Reiterated
08/11/25
Piper Sandler
$40
Buy
3074.60%
Upside
Reiterated
08/07/25
Chardan Capital
$9
Buy
614.29%
Upside
Reiterated
08/07/25
Leerink Partners
$3
Buy
138.10%
Upside
Reiterated
08/07/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$5
Buy
296.83%
Upside
Reiterated
09/02/25
Canaccord Genuity
$6
Buy
376.19%
Upside
Reiterated
08/29/25
Promising Developments and Strategic Approaches in Tenaya Therapeutics' Gene Therapy Programs Drive Buy RatingTNYA has 2 data updates coming in 4Q25: one from TN-201 for the treatment of MYBPC3-associated HCM (longer cohort 1 follow up and initial cohort 2 data) and another from its 2nd program TN-401 for PKP2-ARVC (initial cohort 1 data). Ahead of these updates the co hosted a webcast (slides here, replay here) to dive into the nuance of protein expression and measurement in both diseases. As a reminder, there is not a clear "threshold" or target protein level in either disease. Instead, the goal is to increase protein levels from baseline, and even modest changes may provide clinically meaningful benefit. As such, ability to accurately measure small changes in protein level is critical, and the webcast focused on TNYA's collaboration with Dr. Michael Previs (U of Vermont) to develop its mass spec based quantification assays for both programs.
LifeSci Capital
$3
Buy
138.10%
Upside
Reiterated
08/29/25
Promising Advancements and Strategic Approaches Underpin Buy Rating for Tenaya TherapeuticsTenaya Therapeucs (Nasdaq: TNYA) hosted a KOL event with Dr. Michael Previs, a leading cardiac protein quanfic aon expert, who shared his experse, experience, and insights into quanfic aon methods being used in Tenaya’s ongoing clinical studies for MYBPC3- HCM (with TN-201) and PKP2-ARVC (with TN-401). Importantly, Tenaya and Dr. Previs shared insights into their approach to normalizing cardiac protein expression, which focuses on normalizing to a consistently expressed cardiomyocyte-specific proteins like myosin heavy chain (MYH-6/7) vs more tradional references like GAPDH. Here, Dr. Previs generated historical data using liquid chromatography–mass spectrometry (LCMS or mass-spec) to analyze cardiac ssue from MYBPC3-HCM paen ts and donor controls.
William Blair
―
Buy
―
Reiterated
08/26/25
Morgan Stanley
$5
Buy
296.83%
Upside
Reiterated
08/26/25
TD Cowen
―
Buy
―
Reiterated
08/11/25
Piper Sandler
$40
Buy
3074.60%
Upside
Reiterated
08/07/25
Chardan Capital
$9
Buy
614.29%
Upside
Reiterated
08/07/25
Leerink Partners
$3
Buy
138.10%
Upside
Reiterated
08/07/25
Best Analysts Covering Tenaya Therapeutics
1 Month
xxx
Success Rate
7/15 ratings generated profit
Average Return
+12.92%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 46.67% of your transactions generating a profit, with an average return of +12.92% per trade.
3 Months
xxx
Success Rate
8/14 ratings generated profit
Average Return
+20.56%
reiterated a xxx
rating 21 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +20.56% per trade.
1 Year
Success Rate
8/15 ratings generated profit
Average Return
+21.37%
reiterated a buy rating 17 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +21.37% per trade.
2 Years
xxx
Success Rate
8/15 ratings generated profit
Average Return
+26.69%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 53.33% of your transactions generating a profit, with an average return of +26.69% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
TNYA Analyst Recommendation Trends
Rating
Apr 25
May 25
Jul 25
Aug 25
Sep 25
Strong Buy
17
21
11
18
14
Buy
3
5
3
6
4
Hold
1
1
0
0
0
Sell
2
2
1
0
0
Strong Sell
0
0
0
0
0
total
23
29
15
24
18
Each month's total comprises the sum of three months' worth of ratings.
TNYA Financial Forecast
TNYA Stock Forecast FAQ
What is TNYA’s average 12-month price target, according to analysts?
Based on analyst ratings, Tenaya Therapeutics’s 12-month average price target is 10.14.
What is TNYA’s upside potential, based on the analysts’ average price target?
Tenaya Therapeutics has 704.76% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TNYA a Buy, Sell or Hold?
Tenaya Therapeutics has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
What is Tenaya Therapeutics’s price target?
The average price target for Tenaya Therapeutics is 10.14. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $3.00. The average price target represents 704.76% Increase from the current price of $1.26.
The highest analyst price target is $40.00 ,the lowest forecast is $3.00. The average price target represents 704.76% Increase from the current price of $1.26.
What do analysts say about Tenaya Therapeutics?
Tenaya Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of TNYA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.